Objective To evaluate and summarize the evidence regarding the management of immune checkpoint inhibitor-related cutaneous toxicity, and to provide a basis for healthcare professionals to manage cancer patients developing immune checkpoint inhibitor-related cutaneous toxicity. Methods A systematic search was conducted in relevant domestic and international websites and databases. Guidelines, expert consensus reports, evidence summary reports, systematic reviews, and other evidence on the management of immune checkpoint inhibitor-related cutaneous toxicity in cancer patients were included. The search timeframe was from database inception to April 30, 2024. Two researchers with expertise in evidence-based nursing independently assessed the quality and level of evidence of the literature. Results A total of 19 articles were included, comprising 7 guidelines, 10 expert consensus statement reports, 1 systematic review, and 1 clinical decision-making report. Nineteen pieces of best-evidence were formulated from five aspects: prevention, assessment, examination, treatment and care, and monitoring. Conclusion Effective management of immune checkpoint inhibitor-related cutaneous toxicity can alleviate cutaneous symptoms and improve patients′ quality of life. Healthcare professionals should consider patients′ preferences and tailor personalized guidance based on clinical circumstances for patients with immune checkpoint inhibitor-related cutaneous toxicity in cancer treatment.